Kleiter and colleagues suggested testing for anti-AQP4 and anti-MOG antibodies in patients diagnosed with MS before initiating natalizumab therapy, although a percentage of patients with NMOSD could be seronegative. The gene discussed is AQP4; the disease is myeloid sarcoma.